Should You Buy Outset Medical, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Outset Medical, Inc. (OM) occupies a solid middle-ground position with a Quality of Company score of 6.1/10. At the current market price of $3.14, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 1 of 3 CirclFi valuation models project upside for Outset Medical, Inc. (OM) at $3.14 — the model consensus leans bearish, with a Quality Score of 6.1/10 and Value-Trap risk of 26/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Outset Medical, Inc. (OM) in 2026?
What Is the Bull Case vs the Bear Case for Outset Medical, Inc. (OM)?
| Bull case — $9.89 target (+214.9%) | Bear case — $0.76 target (-75.8%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the PWERM model targets a fair value of $9.89 (+214.9%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.76 (-75.8%), suggesting that the market price embeds overly optimistic growth assumptions. |
| Industry tailwind: licensing and M&A optionality could provide meaningful support for Outset Medical, Inc.'s revenue and margin trajectory in the Medical Devices space. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +290.7% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry headwind: generic/biosimilar competition represents a meaningful risk for Outset Medical, Inc. and its Medical Devices peers. |
How Does OM Compare to Its Medical Devices Peers?
Valuation data pages: STIM · NSPR · OFIX · CBLL · CVRX · AVR · MDAI · GMED · LUNG · IRMD · PODD
Which Other Stocks Score Like OM on Quality?
Closest companies to OM’s Quality of Company score of 6.1/10, across all industries.
- HHS — Harte Hanks, Inc. (QOC 6.1) · analysis
- IOVA — Iovance Biotherapeutics, Inc. (QOC 6.1) · analysis
- STWI — Stagewise Strategies Corp. (QOC 6.1) · analysis
- UEC — Uranium Energy Corp. (QOC 6.1) · analysis
- IMDX — Insight Molecular Diagnostics Inc. (QOC 6.1) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does OM Appear In?
So Is Outset Medical, Inc. (OM) Worth Buying in 2026?
Caution dominates our read on Outset Medical, Inc. at $3.14. 2 of 3 models see limited upside or outright downside, with the median fair value at $2.90 (-7.6%). Quality at 6.1/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.
These are quantitative model outputs, not investment recommendations. Outset Medical, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About OM Stock?
Should I buy OM stock right now?
Based on CirclFi's multi-model analysis, 1 of 3 models see upside for OM at $3.14. The models are divided, which means the investment case depends heavily on your assumptions about Outset Medical, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Outset Medical, Inc.?
Key risks include: limited model coverage (3/13 active), reducing analytical confidence; wide model disagreement (1199% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does OM compare to its competitors?
Among Medical Devices peers, OM holds a Quality Score of 6.1/10. Comparable companies include STIM (QOC 6.2), NSPR (QOC 6.1), OFIX (QOC 6.2). The relative ranking helps investors identify whether OM offers better fundamental quality than alternatives in the same sector.
Is OM a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. OM's Quality Score of 6.1/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy OM at?
CirclFi does not provide target buy prices or price alerts. However, our 3 active models produce fair value estimates ranging from $0.76 to $9.89. At $3.14, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for OM.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad